The present invention provides methods of specifically targeting compounds
to cells overexpressing matrix metalloproteinases, plasminogen
activators, or plasminogen activator receptors, by administering a
compound and a mutant protective antigen protein comprising a matrix
metalloproteinase or a plasminogen activator-recognized cleavage site in
place of the native protective antigen furin-recognized cleavage site,
wherein the mutant protective antigen is cleaved by a matrix
metalloproteinase or a plasminogen activator overexpressed by the cell,
thereby translocating into the cell a compound comprising a lethal factor
polypeptide comprising a protective antigen binding site.